



Labilor[®] 90

Ticagrelor



Keep Blood *Flowing*

Keep Life *Going*

Labilor[®] 90

Ticagrelor



16%

decrease in the composite primary endpoint of CV Death, MI or Stroke versus Clopidogrel ⁽¹⁾

Indications:

| ACS or a History of MI | Acute Ischemic Stroke or TIA* |
|--|---|
| <ul style="list-style-type: none">To reduce the risk of CV* Death, MI*, and stroke ⁽¹⁾To reduce the risk of stent thrombosis in ACS* stented patients ⁽¹⁾ | <ul style="list-style-type: none">To reduce the risk of stroke ⁽²⁾ |

Dosage and Administration:

| | |
|---|--|
| 180mg Loading Dose followed by 90mg Twice Daily for One year. | 180mg Loading Dose followed by 90mg Twice Daily for up to 30 days. |
|---|--|

No Dosage Adjustment

in patients with **renal impairment** or patients with **mild hepatic impairment**



* CV: Cardiovascular | * MI: Myocardial Infarction
* ACS: Acute Coronary Syndrome | * TIA: Transient Ischemic Attack

References:

- 1) PLATO Study : Lars Wallentin, M.D., Ph.D., et al. : Platelet Inhibition and Patient Outcomes, N Engl J Med 2009;361:1045-57.
- 2) THALES Study : S. Claiborne Johnston, M.D., Ph.D., et al. : Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med 2020;383:207-17.



Zouk el Khrab 104, Dbayeh
P.O. Box: 70 31, Lebanon
T. +961 4 545000 • F. +961 4 541333
info@bpi.com.lb • www.bpi.com.lb

DOWNLOAD OUR
MOBILE APP

The Easiest Way to access your available medicines from Benta. Anywhere, Anytime!



Download on the
App Store



GET IT ON
Google Play